ReNerve Ltd (ASX: RNV)

Transforming Nerve Repair Through Science and Improving Patient Outcomes.

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

We've received marketing approval for our NervAlign® Nerve Cuff in Indonesia. Indonesia joins ReNerve's growing Asia-Pacific footprint alongside the United States, New Zealand, Hong Kong, Thailand and Malaysia.

As the world's fourth most populous nation, with over 280 million people, Indonesia represents one of the largest single-country opportunities in our regional strategy. The approval opens access to Southeast Asia's largest economy and one of the region's most significant addressable markets for nerve repair.

This approval is a significant milestone in our Asia-Pacific expansion strategy, and we look forward to working with our partners to bring the NervAlign® Nerve Cuff to Indonesian clinicians and patients.

Read the full $RNV ASX Announcement here: https://t.co/azQ305piTe

#NerveRepair #PeripheralNerveRepair #Indonesia #MedicalDevices #AsiaPacific #MedTech

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

When it comes to peripheral nerve repair, having the right product available at the right time matters. ReNerve's FDA-cleared NervAlign® Nerve Cuff is designed to protect repaired nerves while supporting the body's natural healing process. It is manufactured using the eCOO® method, which uses supercritical CO₂ to remove unwanted immunogenic material while maintaining the tissue’s native structure. NervAlign® is designed to minimise inflammatory responses and scarring while maintaining the tissue's natural structure.

NervAlign® is pliable, easy to trim and easily affixed. It is designed to support surgical handling while protecting the repair site.

It's another example of how thoughtful biomaterial design can support surgeons, hospitals and ultimately patient outcomes.

$RNV #ASX #PeripheralNerveRepair #HandSurgery #PlasticSurgery #Orthopaedics #MedTech

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

Not all biomaterials are created equal. Decellularization, crosslinking and sterilization help transform porcine-derived tissue into a biocompatible scaffold designed to support tissue integration and remodeling.

At ReNerve, biomaterials are at the core of our product development programs focused on peripheral nerve repair and related surgical applications.

$RNV #ReNerve #ASXRNV #Empliq #MedicalDevices #Healthcare #Biotechnology #Biologics #MedTech

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

We've entered into a product supply partnership agreement with Texas-based J4 as a second approved manufacturer of our Empliq™ product range.

The partnership is driven by accelerating commercial traction and increased market demand, with a dual-supplier strategy that strengthens supply chain resilience and scales manufacturing capacity to support growth.

With several recent new hospital approvals for Empliq™, the partnership enables us to fulfil expanding order volumes, shorten lead times for customers and improve product availability.

The appointment reflects our confidence in Empliq™'s commercial trajectory and our commitment to meeting market demand.

Read more: https://t.co/J07b0X7u1R

$RNV #ReNerve #ASXRNV #Empliq #MedicalDevices #Healthcare #Biotechnology

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

Our team will be attending the ESSER Masterclass Malaysia in Kuala Lumpur from 12–14 June.

The three-day program covers hand flaps, nerve repair, tendon techniques and fracture management, bringing together surgeons focused on improving outcomes in hand and peripheral nerve surgery.

If you're attending, visit us at Table 3 to learn more about ReNerve's growing portfolio of products for peripheral nerve repair, including the FDA-cleared NervAlign® Nerve Cuff.

We look forward to connecting with surgeons and healthcare professionals from across the region.
$RNV #ReNerve #ASX #HandSurgery #NerveRepair #PeripheralNerveRepair #MedTech #ESSER #PlasticSurgery

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

We've partnered with UG Medical as our commercialisation partner for the NervAlign products in the Malaysian market.

UG Medical is an established medical device distributor with an extensive network across Malaysia, a market with a population of approximately 33 million people and a rapidly growing healthcare sector.

NervAlign received regulatory clearance in Malaysia earlier this year via the Medical Device Authority (MDA), and we are looking to launch our nerve conduit product later this year.

Commercialisation will be supported by our Asia sales and marketing team, and we will be a major sponsor for the hand surgery teaching event in Kuala Lumpur in June 2026.

Read the full $RNV ASX Announcement: https://t.co/cf0VqtegkO

#ReNerve #ASXRNV #NerveRepair #MedicalDevices #Malaysia #HandSurgery #PeripheralNerveRepair

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

ReNerve signs distribution agreement to expand into Hong Kong and Greater Bay Area | $RNV Media coverage by Proactive.

https://t.co/0QcFtCRZvb
#RNV #ReNerve #ASXNews

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

We've partnered with Swedish Trading Company (STC) to commercialise ReNerve NervAlign products across Hong Kong, Macau and the Greater Bay Area, following our recently announced expanded product approval across those jurisdictions.

The agreement covers the Hong Kong, Macau and Greater China Bay Area markets, representing a combined addressable population of approximately 88 million people.

STC brings an established network of hospitals and surgeons across the region and a proven track record in commercialising innovative medical technologies.

We are currently shipping the first stocking orders to the Hong Kong region.

Read the full $RNV ASX Announcement: https://t.co/ABAv60w7YO

#ReNerve #ASXRNV #NerveRepair #MedicalDevices #HongKong #Healthcare #PeripheralNerveRepair

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

New research continues to highlight the growing role regenerative medicine may play in peripheral nerve repair.

A recent peer-reviewed review published in Orthopedic Review (2025) explores how stem cell therapies, exosomes and related technologies could help address key challenges in peripheral nerve injuries (PNIs), including inflammation, scar formation and inconsistent functional recovery.

PNIs impact an estimated 2–3% of trauma patients, and traditional repair methods can still face limitations including scar formation, donor site morbidity, and inconsistent functional recovery.

The review highlights several promising areas in regenerative medicine for peripheral nerve repair, including the potential of mesenchymal stem cells (MSCs), MSC secretome and stem cell-derived exosomes to support regeneration and modulate inflammation. Adipose-derived MSCs (AD-MSCs) are also gaining attention for their accessibility, scalability, and regenerative potential.

At ReNerve, we're developing products designed to support nerve protection, regeneration and recovery across a range of peripheral nerve repair applications.

Read the review here:
https://t.co/z47fgKU1nq $RNV

#ReNerve #ASX #RNV #NerveRepair #HandSurgery #RegenerativeMedicine #MedTech

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

What does a hand surgeon actually care about when reinforcing a nerve repair?
1. Zero tension at the coaptation site
2. Axons that stay aligned & on track
3. A barrier that stops scar tissue from derailing healing
ReNerve's NervAlign® Nerve Cuff is built for exactly this. $RNV

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

Peripheral nerve repair doesn’t stop at reconnection. Managing scarring and adhesions can make a real difference to outcomes.
Our FDA-cleared NervAlign® Nerve Cuff is designed to protect the repair site and support recovery.
Learn more: https://t.co/FmPCWAtanM $RNV

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

Our replay from today's webinar discussing the March 2026 quarterly report, as well as further updates for the Company, is now available.

View the full $RNV replay here: https://t.co/JifGzcHQDy

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

We have released our May Quarterly Investor Presentation - “Transforming Nerve Repair Through Science”

View the presentation here:
https://t.co/CwQWOxu2rN

Register to watch the webinar replay:
https://t.co/SbgGqcpBkK

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

We’re proud to have our team at the 50th Annual Vanderbilt Orthopaedic Society Meeting, alongside our partners at M2. Great to hear surgeons share real cases & discuss practical ways to improve outcomes strong alignment with $RNV ’s focus on nerve protection and regeneration.

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

We've released our Q3 FY26 Activities Report and Appendix 4C
View the full $RNV report here: https://t.co/CdLT9qvHmn

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

ReNerve’s NervAlign Nerve Guide Matrix Enters Critical Stage 3 Development | $RNV Media coverage by @sharecafetweets.

https://t.co/ZWrSjiX2Rh

[StockWire X | ASX News @StockWireX]

@ReNerveLtd outlines path to FDA submission as NervAlign Nerve Guide Matrix enters Stage 3 verification $RNV

https://t.co/WwwCbjGGDe

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

We've entered stage 3 of the scaled commercial production process for our NervAlign Nerve Guide Matrix in preparation for FDA submission.
Read the full $RNV ASX Announcement here: https://t.co/v5SeCZtMSL

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

“Peripheral nerves… help us run, walk, jump and move… and they have the ability to regenerate.” – Dr Julian Chick. Watch the full $RNV presentation to hear our strategy to build a portfolio for peripheral nerve repair.
Watch here: https://t.co/fUwDsf0hLq

[ReNerve Ltd (ASX: RNV) @ReNerveLtd]

ReNerve featured in a recent @Spark_Plus Research Flash Note highlighting $RNV's transition into early commercialisation and expanding global footprint.